LGND Ligand Pharmaceuticals Incorporated

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND

Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November 9, 2015 through November 14, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Ligand investors under the federal securities laws.

To join the Ligand class action, go to http://www.rosenlegal.com/cases-996.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ligand overstated the value of certain Deferred Tax Assets by approximately $27.5 million or 13%; (2) Ligand’s outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015; (3) Ligand did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions; (4) in turn, Ligand lacked effective internal control over financial reporting; and (5) as a result, Defendants’ statements about Ligand’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-996.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

EN
18/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc: 1 director

A director at Ligand Pharmaceuticals Inc sold 1,804 shares at 188.310USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

 PRESS RELEASE

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound annual growth rate$1 billion in deployable capital expected to drive long-term royalty revenue growth JUPITER, Fla., Dec. 09, 2025 (GLOBE ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidanc...

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings per diluted share1 increased to $7.40 - $7.65 (previously $6.70 - $7.00) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended Sept...

 PRESS RELEASE

Ligand to Participate in November Investor Conferences

Ligand to Participate in November Investor Conferences JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: UBS Global Healthcare Conference (Palm Beach Gardens): Management will participate in one-on-one meetings on November 10, 2025.Stifel 2025 Healthcare Conference (New York): Management will participate in a fireside chat on November 12, 2025 at 8:40 a.m. ET. Southwest IDEAS 20...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch